French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by ...
Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...
Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...
Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...
On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...
Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat ...
The French pharmaceutical company posted better-than-expected earnings and sales in the third quarter, boosted by ...
French drug major Sanofi (SNYNF, SNY) reported third quarter net income attributable to equity holders of the company of 2.82 billion ...
Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance ...
As Sanofi prepares to halt U.S. marketing of its dengue vaccine in 2026, locally acquired infections in the country are ...
ph.investing.com on MSN8h
Sanofi shares rise as Q3 results beat forecasts on vaccines and Beyfortus salesSanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, buoyed by strong vaccine revenues and robust early sales of Beyfortus, its ...
The U.K. will study whether Lilly's weight loss drug can get people back to work and help tackle long-term sickness ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback